hydralazine has been researched along with Stroke in 16 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 9.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "This study aimed to compare the effects of labetalol, nicardipine, or hydralazine on time to target blood pressure before alteplase administration in patients with acute ischemic stroke." | 7.81 | Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine. ( Cortes, J; Hall, AB; McKay, C, 2015) |
| " Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP)." | 7.75 | Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. ( Araki, S; Hirooka, Y; Kishi, T; Sunagawa, K; Utsumi, H; Yasukawa, K, 2009) |
| " Despite comparable hypotensive effects between valsartan and hydralazine in salt-loaded SHRSP, valsartan reduced cerebral NADPH oxidase activity and ROS more than hydralazine being accompanied by more prevention of stroke by valsartan than hydralazine." | 7.74 | Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E, 2008) |
| "To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat." | 7.74 | Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008) |
| " Azelnidipine, hydralazine, or vehicle was orally administered for 28 days to stroke-prone spontaneously hypertensive rats." | 7.74 | Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. ( Araki, S; Hirooka, Y; Kishi, T; Koga, Y; Konno, S; Sunagawa, K, 2008) |
| " The antistroke effects of captopril treatment occurred without an antihypertensive effect, weren't altered by enhancing hypertension during treatment (with dexamethasone), and couldn't be duplicated by antihypertensive treatment with hydralazine." | 7.70 | Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats. ( King, SR; Smeda, J; Vasdev, S, 1999) |
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 5.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| " Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia." | 4.98 | Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018) |
| "Results suggest that perfusion can be augmented in ischemic stroke with norepinephrine and hydralazine." | 4.31 | Augmentation of perfusion with simultaneous vasodilator and inotropic agents in experimental acute middle cerebral artery occlusion: a pilot study. ( Carroll, T; Christoforidis, GA; Jeong, YI; Liu, M; Niekrasz, M; Roth, S; Saadat, N, 2023) |
| "This study aimed to compare the effects of labetalol, nicardipine, or hydralazine on time to target blood pressure before alteplase administration in patients with acute ischemic stroke." | 3.81 | Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine. ( Cortes, J; Hall, AB; McKay, C, 2015) |
| " Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP)." | 3.75 | Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. ( Araki, S; Hirooka, Y; Kishi, T; Sunagawa, K; Utsumi, H; Yasukawa, K, 2009) |
| " Despite comparable hypotensive effects between valsartan and hydralazine in salt-loaded SHRSP, valsartan reduced cerebral NADPH oxidase activity and ROS more than hydralazine being accompanied by more prevention of stroke by valsartan than hydralazine." | 3.74 | Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E, 2008) |
| "To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat." | 3.74 | Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008) |
| " Azelnidipine, hydralazine, or vehicle was orally administered for 28 days to stroke-prone spontaneously hypertensive rats." | 3.74 | Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. ( Araki, S; Hirooka, Y; Kishi, T; Koga, Y; Konno, S; Sunagawa, K, 2008) |
| " We evaluated the effects of combining an angiotensin II type 1 (AT1) receptor blocker (ARB, valsartan) and a NEPI (CGS 25354) in comparison with a dual ACEI/NEPI (CGS 30440) in stroke-prone spontaneously hypertensive rats (SHRSP)." | 3.74 | Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. ( Amiri, F; Brassard, P; Iglarz, M; Javeshghani, DM; Pu, Q; Schiffrin, EL; Webb, RL, 2008) |
| " Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
| " The antistroke effects of captopril treatment occurred without an antihypertensive effect, weren't altered by enhancing hypertension during treatment (with dexamethasone), and couldn't be duplicated by antihypertensive treatment with hydralazine." | 3.70 | Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats. ( King, SR; Smeda, J; Vasdev, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M | 1 |
| Saadat, N | 1 |
| Jeong, YI | 1 |
| Roth, S | 1 |
| Niekrasz, M | 1 |
| Carroll, T | 1 |
| Christoforidis, GA | 1 |
| Carrera, JF | 1 |
| Sorace, BJ | 1 |
| Worrall, BB | 1 |
| Southerland, AM | 1 |
| Chiota-McCollum, NA | 1 |
| Wiggers, H | 1 |
| Køber, L | 1 |
| Gislason, G | 1 |
| Schou, M | 1 |
| Poulsen, MK | 1 |
| Vraa, S | 1 |
| Nielsen, OW | 1 |
| Bruun, NE | 1 |
| Nørrelund, H | 1 |
| Hollingdal, M | 1 |
| Barasa, A | 1 |
| Bøttcher, M | 1 |
| Dodt, K | 1 |
| Hansen, VB | 1 |
| Nielsen, G | 1 |
| Knudsen, AS | 1 |
| Lomholdt, J | 1 |
| Mikkelsen, KV | 1 |
| Jonczy, B | 1 |
| Brønnum-Schou, J | 1 |
| Poenaru, MP | 1 |
| Abdulla, J | 1 |
| Raymond, I | 1 |
| Mahboubi, K | 1 |
| Sillesen, K | 1 |
| Serup-Hansen, K | 1 |
| Madsen, JS | 1 |
| Kristensen, SL | 1 |
| Larsen, AH | 1 |
| Bøtker, HE | 1 |
| Torp-Petersen, C | 1 |
| Eiskjær, H | 1 |
| Møller, J | 1 |
| Hassager, C | 1 |
| Steffensen, FH | 1 |
| Bibby, BM | 1 |
| Refsgaard, J | 1 |
| Høfsten, DE | 1 |
| Mellemkjær, S | 1 |
| Gustafsson, F | 1 |
| Watson, K | 1 |
| Broscious, R | 1 |
| Devabhakthuni, S | 1 |
| Noel, ZR | 1 |
| McKay, C | 1 |
| Hall, AB | 1 |
| Cortes, J | 1 |
| Yee, J | 1 |
| Yamamoto, E | 1 |
| Tamamaki, N | 1 |
| Nakamura, T | 2 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Fukuda, M | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Kato, N | 1 |
| Liang, YQ | 1 |
| Ochiai, Y | 1 |
| Birukawa, N | 1 |
| Serizawa, M | 1 |
| Jesmin, S | 1 |
| Konno, S | 1 |
| Hirooka, Y | 2 |
| Araki, S | 2 |
| Koga, Y | 1 |
| Kishi, T | 2 |
| Sunagawa, K | 2 |
| Yasukawa, K | 1 |
| Utsumi, H | 1 |
| NOZAWA, G | 1 |
| HOSHINO, T | 1 |
| Pu, Q | 1 |
| Brassard, P | 1 |
| Javeshghani, DM | 1 |
| Iglarz, M | 1 |
| Webb, RL | 1 |
| Amiri, F | 1 |
| Schiffrin, EL | 1 |
| Smeda, J | 1 |
| Vasdev, S | 1 |
| King, SR | 1 |
| Ikeda, Y | 1 |
| Takano, H | 1 |
| Kimura, H | 1 |
| Obata, JE | 1 |
| Takeda, S | 1 |
| Hata, A | 1 |
| Shido, K | 1 |
| Mochizuki, S | 1 |
| Yoshida, Y | 1 |
| Nakaya, H | 1 |
| Sasamura, H | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
| Tejima, E | 1 |
| Katayama, Y | 1 |
| Suzuki, Y | 1 |
| Kano, T | 1 |
| Lo, EH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M[NCT03514108] | Phase 4 | 1,500 participants (Anticipated) | Interventional | 2018-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydralazine and Stroke
| Article | Year |
|---|---|
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri | 2018 |
1 trial available for hydralazine and Stroke
| Article | Year |
|---|---|
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr
Topics: Aged; Chronic Disease; Denmark; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; H | 2021 |
14 other studies available for hydralazine and Stroke
| Article | Year |
|---|---|
Augmentation of perfusion with simultaneous vasodilator and inotropic agents in experimental acute middle cerebral artery occlusion: a pilot study.
Topics: Animals; Brain Ischemia; Cerebrovascular Circulation; Dogs; Hydralazine; Infarction, Middle Cerebral | 2023 |
Delay to Tissue Plasminogen Activator in Hypertensive Stroke Patients: An Analysis of Delay Duration Across Agents.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Administration Schedule; Female; Fibrinolytic Ag | 2020 |
Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Female; Fib | 2015 |
PGX: Pharmacogenomics During Generation X.
Topics: Anticoagulants; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heart Failure; H | 2016 |
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
Topics: Acetophenones; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Astrocytes; Blood Pressu | 2008 |
Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimida | 2008 |
Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Antioxidants; Azetidinecarboxylic Acid; Bloo | 2008 |
Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Brain; El | 2009 |
[ON APOPLEXY IN A CERTAIN REGION AND THE PROPHYLACTIC USE OF ANTIHYPERTENSIVE AGENTS].
Topics: Adolescent; Antihypertensive Agents; Benzothiadiazines; Cerebrovascular Disorders; Child; Epidemiolo | 1964 |
Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Ther | 2008 |
Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Blood Pressure; Captopril; | 1999 |
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |
Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model.
Topics: Animals; Blood Flow Velocity; Blood Gas Analysis; Blood Pressure; Brain; Cerebral Hemorrhage; Cerebr | 2001 |